Back to Search

Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  • Protocol Number: 202402201
  • Principal Investigator: Robinson, Clifford
  • Cancer Types: Lung

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Protocol Interventions

Drug: RYZ101 Dose Level 1, Drug: RYZ101 Dose Level 2, Drug: RYZ101 Dose Level 3, Drug: RYZ101 Dose Level -1, Drug: Atezolizumab, Drug: Carboplatin, Drug: Etoposide